CN111378610A - 一种巴弗洛霉素高产工程菌及其构建和应用 - Google Patents
一种巴弗洛霉素高产工程菌及其构建和应用 Download PDFInfo
- Publication number
- CN111378610A CN111378610A CN201811634377.7A CN201811634377A CN111378610A CN 111378610 A CN111378610 A CN 111378610A CN 201811634377 A CN201811634377 A CN 201811634377A CN 111378610 A CN111378610 A CN 111378610A
- Authority
- CN
- China
- Prior art keywords
- bafilomycin
- lohii
- gene
- bafg
- engineering bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XDHNQDDQEHDUTM-UHFFFAOYSA-N bafliomycin A1 Natural products COC1C=CC=C(C)CC(C)C(O)C(C)C=C(C)C=C(OC)C(=O)OC1C(C)C(O)C(C)C1(O)OC(C(C)C)C(C)C(O)C1 XDHNQDDQEHDUTM-UHFFFAOYSA-N 0.000 title claims abstract description 54
- 229930192649 bafilomycin Natural products 0.000 title claims abstract description 51
- 241000894006 Bacteria Species 0.000 title claims abstract description 43
- 238000010276 construction Methods 0.000 title abstract description 15
- 241000833571 Streptomyces lohii Species 0.000 claims abstract description 72
- 108700005075 Regulator Genes Proteins 0.000 claims abstract description 21
- 101100038645 Streptomyces griseus rppA gene Proteins 0.000 claims abstract description 21
- 238000000855 fermentation Methods 0.000 claims abstract description 19
- 230000004151 fermentation Effects 0.000 claims abstract description 19
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 18
- 239000013598 vector Substances 0.000 claims description 17
- 230000002018 overexpression Effects 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 8
- 241000588724 Escherichia coli Species 0.000 claims description 7
- 239000013604 expression vector Substances 0.000 claims description 7
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000010367 cloning Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 241001655322 Streptomycetales Species 0.000 claims description 4
- 229960003276 erythromycin Drugs 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 3
- 101150068419 ORF 1 gene Proteins 0.000 claims description 2
- 239000002994 raw material Substances 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 4
- 238000010353 genetic engineering Methods 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 101100437895 Alternaria brassicicola bsc3 gene Proteins 0.000 description 21
- 101150073872 ORF3 gene Proteins 0.000 description 21
- 101100226891 Phomopsis amygdali PaP450-1 gene Proteins 0.000 description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 239000002609 medium Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- XZNUGFQTQHRASN-XQENGBIVSA-N apramycin Chemical compound O([C@H]1O[C@@H]2[C@H](O)[C@@H]([C@H](O[C@H]2C[C@H]1N)O[C@@H]1[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O1)O)NC)[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O)[C@H]1O XZNUGFQTQHRASN-XQENGBIVSA-N 0.000 description 7
- 229950006334 apramycin Drugs 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 102000006270 Proton Pumps Human genes 0.000 description 6
- 108010083204 Proton Pumps Proteins 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 229960000268 spectinomycin Drugs 0.000 description 6
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 238000003208 gene overexpression Methods 0.000 description 5
- XDHNQDDQEHDUTM-XJKSCTEHSA-N (3z,5e,7r,8s,9r,11e,13e,15s,16r)-16-[(2s,3r,4s)-4-[(2r,4r,5s,6r)-2,4-dihydroxy-5-methyl-6-propan-2-yloxan-2-yl]-3-hydroxypentan-2-yl]-8-hydroxy-3,15-dimethoxy-5,7,9,11-tetramethyl-1-oxacyclohexadeca-3,5,11,13-tetraen-2-one Chemical compound CO[C@H]1\C=C\C=C(C)\C[C@@H](C)[C@H](O)[C@H](C)\C=C(/C)\C=C(OC)\C(=O)O[C@@H]1[C@@H](C)[C@@H](O)[C@H](C)[C@]1(O)O[C@H](C(C)C)[C@@H](C)[C@H](O)C1 XDHNQDDQEHDUTM-XJKSCTEHSA-N 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101150067314 aadA gene Proteins 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 101150016512 luxR gene Proteins 0.000 description 3
- 229960000210 nalidixic acid Drugs 0.000 description 3
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 101710205660 Calcium-transporting ATPase Proteins 0.000 description 2
- 101710134161 Calcium-transporting ATPase sarcoplasmic/endoplasmic reticulum type Proteins 0.000 description 2
- 201000007336 Cryptococcosis Diseases 0.000 description 2
- 241000221204 Cryptococcus neoformans Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 241001587868 Streptomyces marinus Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 101150045195 afsR gene Proteins 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 210000004957 autophagosome Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 108091008053 gene clusters Proteins 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Inorganic materials [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229940122739 Calcineurin inhibitor Drugs 0.000 description 1
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 description 1
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 description 1
- 101000936911 Chionoecetes opilio Sarcoplasmic/endoplasmic reticulum calcium ATPase Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000006870 ms-medium Substances 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical group [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003308 potassium ionophore Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000028070 sporulation Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/162—Heterorings having oxygen atoms as the only ring heteroatoms, e.g. Lasalocid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/76—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Actinomyces; for Streptomyces
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明属于生物技术和基因工程领域，具体的讲，是一种巴弗洛霉素高产工程菌及其构建和应用。在Streptomyces lohii野生株或突变株中过表达调控基因、其同源基因或与其功能等同体，所述调控基因为bafG和/或orf1；其中，调控基因BafG和Orf1的序列，分别为SEQ ID NO.1和SEQ ID NO.2。本发明构建的工程菌能够稳定生产巴弗洛霉素，发酵原料成本低廉，构建步骤简单，可为巴弗洛霉素的药理学研究提供充足的原料来源，具有广阔的应用前景。
Description
技术领域
本发明属于生物技术和基因工程领域，具体的讲，是一种巴弗洛霉素高产工程菌及其构建和应用。
背景技术
巴弗洛霉素(bafilomycins)属于十六元大环内酯类抗生素，具有广泛的生物活性，如抗细菌[1]，抗真菌[2]，抗寄生虫[3]，抗骨质疏松[4]，抗肿瘤[5]，免疫抑制[3]等。其中最具代表性的化合物当属巴弗洛霉素A1，对酵母菌等真菌具有显著抑制活性[1]。巴弗洛霉素A1是第一个被鉴定的强力且专一的钾离子载体功能的大环内酯抗生素，其可促进线粒体对钾离子的吸收，并在纳摩尔水平发挥作用，引起线粒体膜电势的消失，氧化磷酸化解耦联以及呼吸作用抑制从而造成线粒体的功能损伤[6]。并且，巴弗洛霉素A1是强力的囊泡型质子泵(V-ATPase)抑制剂，对来自大肠杆菌的K+依赖型质子泵，牛脑的钠钾质子泵和肌浆网钙泵(sarco/endoplasmic reticulum Ca2+-ATPase,SERCA)等P型质子泵具有中等强度的抑制活性，对F型质子泵(F-ATPase)无抑制活性[4]。因此，巴弗洛霉素A1在细胞生物学领域已发展为一种用于区分上述三种质子泵以及研究V-ATPase生物学功能的重要工具。除此之外，V-ATPase参与到人类及哺乳动物体内的一系列生理学过程，是一种重要的药物作用靶点[7,8]。例如，巴弗洛霉素A1通过阻止破骨细胞中的V-ATPase质子通道的形成并抑制骨吸收，可在纳摩尔水平发挥作用，有望开发为骨质疏松症的治疗药物[9]。体外药理学研究表明，巴弗洛霉素A1有望应用于癌症治疗，巴弗洛霉素A1可通过抑制V-ATPase可以遏制癌细胞内H+的泵出，降低癌细胞外微环境的酸性，抑制癌细胞的生长繁殖、转移以及化疗抵抗作用，进而引起肿瘤细胞的凋亡[10]；或者通过作用于内质网腔上的肌浆网钙泵从而阻断内质网从胞浆摄取Ca2+，进而抑制自噬体与溶酶体融合形成自噬溶酶体来抑制癌症细胞的自噬，提高其对化疗药物的敏感性[11]。
值得一提的是，巴弗洛霉素A1在药物联合治疗方面展现了巨大的潜力。巴弗洛霉素A1具有抗真菌作用，当与钙调磷酸酶抑制剂FK506联用，FK506和巴弗洛霉素A1对条件性致病真菌新型隐球菌的小抑菌浓度分别降低至0.39和0.06μg/mL，比分别单独用药的剂量降低33倍和1000倍以上[12]；当巴弗洛霉素A1和化疗药物5-氟尿嘧啶联用时可以降低胃癌细胞对5-氟尿嘧啶的耐受[13]。正是因为V-ATPase广泛参与到人体的生命活动，巴弗洛霉素在用于骨质疏松症、癌症等疾病治疗时也会靶向正常细胞造成伤害，从而限制了其临床应用。因此，巴弗洛霉素类化合物构效关系的研究将能够极大的催动该类药物在临床领域进一步发挥作用，巴弗洛霉素的结构复杂性造成其化学全合成存在步骤多、产率低的缺点。如何利用基因工程和发酵工程的方法获得巴弗洛霉素高产菌株，并对该类化合物产生途径进行理性设计获得高效低毒临床药物是极为重要的研究方向。
分离自巴布新几内亚(Papua New Guinea)的皇冠岛(Crown Island)海滩泥沙的海洋链霉菌Streptomyces lohii ATCC BAA-1276在常规发酵条件下可产生巴弗洛霉素A1，C1，B1。我们前期对S.lohii巴弗洛霉素生物合成基因簇(GenBank：GU390405.1)、生物合成途径[14]和其后修饰过程进行了完整阐明[15]，为巴弗洛霉素的高产工程菌株构建和抗生素发酵提供了关键的平台菌株。
发明内容
本发明的目的是提供一种高效生产巴弗洛霉素工程菌的构建及发酵方法。
为实现上述目的，本发明采用技术方案为：
一种巴弗洛霉素高产工程菌，在Streptomyces lohii野生株或突变株中过表达调控基因、其同源基因或与其功能等同体；其中，调控基因为bafG和/或orf1；所述调控基因BafG和Orf1的序列，分别为SEQ ID NO.1和SEQ ID NO.2。
所述突变株为S.lohiiΔorf2&orf3。
所述过表达调控基因、其同源基因或与其功能等同体的启动子来源于红霉素抗性基因启动子ermE*或其功能等同体。
所述过表达调控基因、其同源基因或与其功能等同体的载体为链霉菌整合型载体pSET152或其功能等同体。
一种所述巴弗洛霉素高产工程菌的构建方法，
将调控基因为bafG和/或orf1基因与载体连接，分别克隆得到含有目的基因的表达载体，再分别将该表达载体转化进大肠杆菌，而后分别将转入表达载体的大肠杆菌与S.lohii野生株或突变株整合即获得巴弗洛霉素高产的S.lohii野生株工程菌或巴弗洛霉素高产的S.lohii突变株工程菌。
所述载体为链霉菌整合型载体pSET152或其功能等同体。
进一步的说，1)根据登陆到NCBI的S.lohii巴弗洛霉素生物合成基因簇(GenBank：GU390405.1)获取调控基因bafG和orf1的序列，分别为SEQ ID NO.1和SEQ ID NO.2。
2)结合序列，设计PCR引物，以pSET152-ermE*为骨架，构建afsR家族调控基因bafG和luxR家族调控基因orf1的的过表达载体。
3)在S.lohii野生型菌株中过表达afsR家族调控基因bafG和luxR家族调控基因orf1。经HPLC分析检测发酵产物，对其巴弗洛霉素的产量进行定量，评测两个调控因子对巴弗洛霉素产量的上调效果；
4)进一步的是，在仅产生的巴弗洛霉素A1的S.lohiiΔorf2&orf3，过表达上调倍数更高的luxR家族调控基因orf1得到高产工程菌。
一种巴弗洛霉素高产工程菌的应用，所述工程菌在生产制备巴弗洛霉素中的应用。
所述野生菌的工程菌在生产制备巴弗洛霉素中的应用。
所述突变菌株的工程菌在生产制备巴弗洛霉素A1中的应用。
进一步的说，将工程菌的孢子体于2×YT液体培养基中，30℃，220rpm培养2天，再按照1:10的体积比例转接种子液到发酵培养基中，30℃，250rpm培养7天，收集发酵液经HPLC定量/定性的检测巴弗洛霉素。
所述发酵培养基为大豆油60g/L，葡萄糖20g/L，豆粉20g/L，玉米浆1.5g/L，NZ-amine 2g/L，酵母提取物1g/L，NaNO3 8g/L，NaCl 5g/L，(NH4)2SO4 6g/L，K2HPO4 0.3g/L，CaCO3 8g/L，pH＝7.1；2×YT培养基为胰蛋白胨16g/L，酵母提取物10g/L，NaCl 5g/L。
本发明的有益效果：
利用有机化学合成化学结构复杂的巴弗洛霉素存在反应步骤多，得率低的缺点。本发明构建的工程菌能够稳定生产巴弗洛霉素，构建步骤简单，原料成本低廉，发酵周期短，发酵过程绿色环保；S.lohiiΔorf2&orf3工程菌巴弗洛霉素A1的在250mL摇瓶中发酵7天后的产量可观(535.1±25.0mg/L)，可为巴弗洛霉素A1的药理学、合成化学研究提供充足的原料来源，具有广阔的应用前景。
附图说明
图1为本发明实施例提供的突变株PCR验证。注：WT：S.lohii野生型；1：S.lohii/pSET152-ermE*；2：S.lohii/pSET152-ermE*-bafG；3：S.lohii/pSET152-ermE*-orf1；4：S.lohiiΔorf2&orf3；5：S.lohiiΔorf2&orf3/pSET152s-ermE*-orf1；M:DNA marker。
图2为本发明发明实施例提供的HPLC检测图。注：i:巴弗洛霉素A1，C1，B1标准品；ii:S.lohii野生型；iii:S.lohii/pSET152-ermE*；iv:S.lohii/pSET152-ermE*-bafG；v:S.lohii/pSET152-ermE*-orf1；vi:S.lohiiΔorf2&orf3；vii,S.lohiiΔorf2&orf3/pSET152s-ermE*-orf1。
图3为本发明发明实施例提供的巴弗洛霉素A1产量图。注：1:S.lohii野生型；2:S.lohii/pSET152-ermE*；3:S.lohii/pSET152-ermE*-bafG；4:S.lohii/pSET152-ermE*-orf1；5:S.lohiiΔorf2&orf3；6：S.lohiiΔorf2&orf3/pSET152s-ermE*-orf1。
具体实施方式
下面将结合实施例，对本发明作进一步的阐述。但本发明并不局限于此，凡依照本发明公开内容所做出的本领域等同替换，均属于本发明的保护范围。
下面将结合附图和实施例对本发明的实施方案进行详细描述，实施例中所采用的PCR扩增，质粒提取、转化等基础分子生物学实验技术，如无特殊说明，通常按照常规方法操作，具体可参见《分子克隆实验指南》(第三版)(Sambrook J,Russell DW，Janssen K,Argentine J.黄培堂等译，2002，北京：科学出版社)，或按照相关产商提供的说明书执行。
实施例1
1.基因过表达载体构建
构建用于S.lohii野生型调控基因过表达的携带安普霉素抗性基因(aac(IV))的整合型质粒：以S.lohii野生型的基因组为模板，分别以引物BafG-BamHI-FP/BafG-KpnI-RP和Orf1-BamHI-FP/Orf1-KpnI-RP(表1)进行PCR，反应体系如下：5×PrimeSTAR GXL Buffer10μL，200μM dNTPs，4μL DMSO，上下游引物各0.3μM，DNA模板适量(10-100ng)，高保真聚合酶(PrimeSTAR GXL DNA聚合酶)2.5U，ddH2O补足至50μL；反应条件为：98℃预变性5min，98℃变性30s，55-65℃退火15s，68℃延伸(1kb/min，根据目的片段长度设定时间)，反应35个循环，最后68℃延伸10min；分别扩增获得调控基因bafG和orf1的PCR产物；将上述获得调控基因bafG和orf1的PCR产物分别经核酸纯化试剂盒纯化后，利用一步克隆试剂盒将bafG和orf1分别整合到pSET152-ermE*的BamHI位点分别得到调控基因过表达质粒pSET152-ermE*-bafG和pSET152-ermE*-orf1。
构建用于携带安普霉素抗性基因(aac(IV))S.lohiiΔorf2&orf3的调控基因过表达的携带壮观霉素抗性基因(aadA)整合型质粒：以商品化质粒pIJ778作为模板，用Spec-NdeI-FP/Spec-SacI-RP引物对(表1)进行PCR扩增得到壮观霉素抗性基因(aadA)；安普霉素抗性质粒pSET152-ermE*经限制性内切酶SacI酶切后回收质粒骨架，通过一步克隆连接aadA得到壮观霉素抗性的质粒pSET152s-ermE*，并将orf1克隆到红霉素启动子的下游得到壮观霉素抗性的基因过表达载体pSET152s-ermE*-orf1。同样的策略，将bafG克隆到红霉素启动子的下游得到壮观霉素抗性的基因过表达载体pSET152s-ermE*-bafG。
以上构建完成的载体经DNA测序完成序列确证。
表1.实例中用到的引物序列
2.调控基因过表达菌株构建
(1)将pSET152-ermE*-bafG和pSET152-ermE*-orf1转化到大肠杆菌Et12567/pUZ8002中，37℃培养16h。挑取分别携带pSET152-ermE*-bafG或pSET152-ermE*-orf1的大肠杆菌Et12567/pUZ8002到2mL LB培养基(含50μg/mL安普霉素、50μg/mL卡那霉素和12.5μg/mL氯霉素)中，37℃，220rpm培养16h。第二天，将上述两个菌株的种子液分别按照1:100的体积比，转接到20mL含50μg/mL安普霉素、50μg/mL卡那霉素和12.5μg/mL氯霉素的LB培养基，37℃，220rpm，培养至OD600到0.6与1.0之间。4℃，4000rpm离心10min收集菌体，弃上清，分别用20mL LB培养液洗涤两次后，菌液经离心浓缩至500μL，即分别获得Et12567/pUZ8002&pSET152-ermE*-bafG或Et12567/pUZ8002&pSET152-ermE*-orf1的浓缩菌液。
(2)收集于MS培养基(豆粉20g/L，甘露醇20g/L，琼脂粉20g/L)上培养的野生株S.lohii的孢子或突变株(S.lohiiΔorf2&orf3)的孢子，分别将其重悬于5mL 2×YT(胰蛋白胨16g/L，酵母提取物10g/L，NaCl 5g/L)培养液中，6000rpm离心2min后弃去上清用等体积2×YT溶液洗涤3-5次后，6000rpm离心2min后，将孢子悬液浓缩至500μL。野生株或突变株孢子悬液于50℃热激10min后，冷却至常温。
(3)S.lohii工程菌的构建
分别取100μL S.lohii野生型的孢子悬液与100μL提前准备好的Et12567/pUZ8002&pSET152-ermE*-bafG或Et12567/pUZ8002&pSET152-ermE*-orf1的浓缩菌液混合，分别均匀涂布于含50mM MgCl2和50mM CaCl2的MS平板上。于30℃培养12h后，每个MS平板用溶有12.5mg安普霉素和0.5mg萘啶酮酸的1mL无菌水覆盖，待干后，重新放置于30℃条件下培养。待3-5天后，有白色的菌落长出，即为bafG过表达菌株S.lohii/pSET152-ermE*-bafG或orf1过表达菌S.lohii/pSET152-ermE*-orf1菌株。利用同样的策略，转化空载体pSET152-ermE*到S.lohii野生型得到对照突变株S.lohii/pSET152-ermE*。挑取单菌落到含25μg/mL萘啶酮酸和50μg/mL安普霉素的MS培养基。约3天产孢后，接种到4mL 2×YT培养液中，28℃，220rpm培养2天后提取基因组供PCR验证基因型。
(4)S.lohiiΔorf2&orf3工程菌构建
分别取100μL S.lohii突变株S.lohiiΔorf2&orf3的孢子悬液与100μL提前准备好的Et12567/pUZ8002&pSET152s-ermE*-orf1的浓缩菌液混合，分别均匀涂布于含50mMMgCl2和50mM CaCl2的MS平板上。于30℃培养12h后，每个MS平板用溶有经壮观霉素(100μg/mL)和萘啶酮酸(25μg/mL)双抗性筛选后得到转化子，置于30℃条件下培养。待3-5天后，有白色的菌落长出，即为S.lohiiΔorf2&orf3/pSET152s-ermE*-orf1。挑取单菌落接种到4mL2×YT培养液中，28℃，220rpm培养2天后提取基因组供PCR验证基因型。
同样的策略，利用Et12567/pUZ8002&pSET152s-ermE*-bafG与S.lohii突变株S.lohiiΔorf2&orf3的接合转移，可得到S.lohiiΔorf2&orf3工程菌S.lohiiΔorf2&orf3/pSET152s-ermE*-bafG。
3.PCR验证突变株基因型
以突变株S.lohii/pSET152-ermE*，S.lohii/pSET152-ermE*-bafG，S.lohii/pSET152-ermE*-orf1，S.lohiiΔorf2&orf3/pSET152s-ermE*-orf1的基因组为模板，采用通用引物M13F47/M13F-48(表1)，进行PCR初步验证突变株的基因型(参见图1)。BafG过表达菌株S.lohii/pSET152-ermE*-bafG的PCR产物预期大小为2266bp；orf1过表达菌S.lohii/pSET152-ermE*-orf1的PCR产物预期大小为844bp；S.lohiiΔorf2&orf3/pSET152s-ermE*-orf1的PCR产物预期大小为844bp；S.lohiiΔorf2&orf3/pSET152s-ermE*-bafG的PCR产物预期大小为2266bp；空载体pSET152-ermE*转化S.lohii得到对照菌株S.lohii/pSET152-ermE*的PCR产物预期大小为471bp。PCR片段经纯化后进一步送往DNA测序确证。
4.S.lohii野生株和突变株的发酵及HPLC分析
从MS平板，挑取S.lohii野生株、突变株(S.lohiiΔorf2&orf3)、上述获得野生株工程菌(S.lohii/pSET152-ermE*-bafG或S.lohii/pSET152-ermE*-orf1；)或突变株工程菌(S.lohiiΔorf2&orf3/pSET152s-ermE*-orf1)孢子到装有30mL 2×YT液体培养基的250mL锥形瓶中，30℃，220rpm培养2天。按照1:10的体积比例转接种子液到含有30mL发酵培养基(大豆油60g/L，葡萄糖20g/L，豆粉20g/L，玉米浆1.5g/L，NZ-amine 2g/L，酵母提取物1g/L，NaNO3 8g/L，NaCl 5g/L，(NH4)2SO4 6g/L，K2HPO4 0.3g/L，CaCO3 8g/L，pH＝7.1)的250mL锥形瓶中，30℃，250rpm培养7天。取200μL发酵液，加入3倍体积的甲醇后于涡旋振荡仪上振荡10min，14000rpm离心10min，取上清供HPLC检测。选用的色谱柱为赛默飞(Thermo)C18色谱柱(4.6×150mm)，有机相为乙腈，水相为加入0.1％三氟乙酸的超纯水，HPLC检测程序为：60-100％乙腈梯度洗脱15min，100％乙腈等度洗脱8min，100-60％乙腈梯度洗脱2min。以巴弗洛霉素A1，B1，C1的标准品对S.lohii野生株和突变株的巴弗洛霉素发酵产量进行定量，每组进行三个平行实验。经7天发酵后，与野生型菌株相比，携带空载体pSET152-ermE*的突变株(S.lohii/pSET152-ermE*)的巴弗洛霉素总产量无明显变化，过表达bafG的突变株(S.lohii/pSET152-ermE*-bafG)提高了0.5倍，过表达orf1的突变株(S.lohii/pSET152-ermE*-orf1)巴弗洛霉素总产量提高了1.3倍，对巴弗洛霉素产量提高的效果优于bafG；过表达orf1的突变株(S.lohiiΔorf2&orf3/pSET152s-ermE*-orf1)，巴弗洛霉素A1产量可达535.1±25.0mg/L(附图2，3)。由于过表达bafG可上调S.lohii野生株中的巴弗洛霉素的产量(附图2,3)。因此，类似地，将pSET152s-ermE*-bafG转化到阻断巴弗洛霉素A1的后修饰途径从而只积累巴弗洛霉素A1的S.lohiiΔorf2&orf3得到的过表达bafG的突变株(S.lohiiΔorf2&orf3/pSET152s-ermE*-bafG)也达到提高S.lohiiΔorf2&orf3的巴弗洛霉素A1的产量的目的。
SEQ ID NO：1
GTGCACGTGTCGGCGCCGAGGCAGCGCGTGGTCATGGCAGCGCTCCTCCTCAACGCCAACCGGGTGATCTCGGTCGACCGCATCACCGAGTACGTCTGGGACGGCGCCCCGCCGCCGAGTGCCGCCGCGACCGTCCGCACCTACGTGATGCGCCTGCGGCAGTCGCTGGGCGAGCACGCCTCCGCCCGCATCCTCACCCGGGCGCCCGGCTACCTCCTCGAACTCGGGGAGCACGAGAGCGATCTCGGCCAGTTCGCCGCCCACCGCAGGCGCGCGGCGGAGCTGGCCGAGCGCGGAGACCTGGAGGGCTCCTCCGCCGCGCTGGCCGAGGCACTCGCCCTGTGGCGCGAGGAGCCGCTGGCGGACATCCCGTCGCGGACGCTGCGCGATGTGGAGGGACGTTACCTCCAGGAGCTCCGGCTGCAGACCATGGAGCTGCGGTTCGACGCGGAGCTGGCGCTGCTGCGGCACGCCGAGATCGTGCCGGAGCTGGTGCGGCTGGTGCGGGAGCATCCCTTACGGGAGGCCCTGGTGGGCAAGTTGATGCTGGCGCTCTTCCGCTCGGGACGGCAGTCGGAGGCCCTGGACCTCTACCGGCGCACCCGGGTACTGCTCGTCGAACAGCTCGGGGCCGAGCCCGGCGCGGATCTGCGCGAGGTCCACCGGCACATCCTCTCGGCCCACGACCGGCCCCGTACGCCCGACCCGCAGGAGCGGCCCGCCCCGGCCCCGGAGACAGCCGCCGCACCGGCCGCTGCCACGGTCCGGGAAAGATCCTGGCCCGATCCTGCGCAGCTTCCCTCGGTCCCGCTGCCCCTGTCGGCCCGCTCCGACGCACTGGCGCGGGTGCGGCACTTCCTCACGACCGGCACGATGCCCGCGGGCATGGTGGCGACGGCGGTGGTGACCGGCCGGGGCGGTGTCGGCAAGAGCGCCCTGGCCCTGCACGCGGCGCACACCATGCGCGGCTCCTCCGTACACGGCCAGCTCTACGCGGATCTCGGCGGGGCGGAGCGGCCGCTGACCGCCCGGGAGGTGCTGCCGCGGTTCCTGGCGGACCTCGGTGTGCCCCGGGACGAGATCCCCGGGGAGGAGTCGGAGCGGGAGAGCCTCTACCGCTCGCTCACCGCGGGCCGCCGTCTGCTGGTGGTGCTCGACAACGCCTCCGGCGCCGCGCAGGTGCGGCCGCTGATCCCGGGCAGCGGGGGCAGCAGGCTGCTGGTGACCAGCCGGCGGCGGCTGGCCGATCTGGAGGGGGCGCGCACCCTTCTGCTCGGCCCGCTGGACGAGGCCGGGTCGCTGGAGCTGCTGGGCAGCATCGTCGGCACGGCCAGGGTCGGCGGCGAACCACGGGCGGCCCGTACGGTGGTGACGGTCTGCGCGGGCCTGCCGCTGGCGATCCGGATCGCGGGGACCCGGCTGCTGGAACGCCCGCACTGGAGCATCGGGCACCTGGCCCGGCGGCTCACGGAGGCCCCCCGGCTGCTGGACGAACTGTGCGCGGGCGATACCGGTGTCCGGCCCTGCCTGGACGCCGAGGTGGCCGGGCTCCGGCGGTCGGCACCGGGCGGAATCGACCCCGCTGAGGTGCTGGCCGCGCTGGGCGCCGCCGGGGCGTCCTCGGTCTCCGGCGGCGAGGTCGCGGTGATGGTCGGCTGCCCGGAGGCGCAGGCCGAGGAGGCCCTGGACTCCCTGGTCGTGGCGAATCTGCTGGGTGCGCCCGCGGGGGGCCGCTACCGGCTGGACGCGCTGCTTCGGGCGTACGCCCGCGAGCGTGCGCAGGCGGTCGCGGTACGGCGGCACGGCCGCTCCTACATGCGCGCCGGGTGA
(a)序列特征：
·长度：1830bp
·类型：核酸序列
(b)分子类型：脱氧核糖核酸
(c)假设：否
(d)反义：否
(e)最初来源：Streptomyces lohii
(f)特异性名称：bafG
SEQ ID NO：2
GTGACACCGTCAGCGACCTCTGAAGAGACCAAGCCCGCACCGCGGCCGCCGAGGTCCGAGCCCGTCGGCGACGCCCGTCCGGCGGGCGGGGACCCGTCCGCCGGCACGGGTGTCCGGCGGCTGACCGCCGTGGACGTCCGCATCCTGGAAGGTGTCGCGGTCGGCACCCCGACCGTCCGGCTGGCGGCATCGCTCTATCTGAGCCGACAGGGCGTCGAGTACCGCATCGGGCTGATGATGCGCCATTTCCAGGCCGCGAACCGGGCCGCACTGATTTCCCGGGCGCACTCACTCGGTGTGCTGAGCGTCGGGGCATGGCCGCCCCGTGTCCTCCCGGAATTCCTTGAACCCTAG
(a)序列特征：
·长度：354bp
·类型：核酸
(b)分子类型：脱氧核糖核酸
(c)假设：否
(d)反义：否
(e)最初来源：Streptomyces lohii
(f)特异性名称：orf1
参考文献
1.Werner,G.,et al.,Metabolic products ofmicroorganisms.224.Bafilomycins,a new group of macrolideantibiotics.Production,isolation,chemical structure and biological activity.JAntibiot 1984.37(2):p.110-117.
2.Kinashi,H.,K.Someno,and K.Sakaguchi,Isolation and characterizationof concanamycins A,B and C.J Antibiot 1984.37(11):p.1333-1343.
3.Goetz,M.A.,et al.,L-155,175:a new antiparasitic macrolidefermentation,isolation and structure.The Journal of antibiotics,1985.38(2):p.161-168.
4.Bowman,E.J.,A.Siebers,and K.Altendorf,Bafilomycins:a class ofinhibitors of membrane ATPases from microorganisms,animal cells,and plantcells.Proc Natl Acad Sci,1988.85(21):p.7972-7976.
5.Wilton,J.,G.Hokanson,and J.C.French,PD 118,576:A new antitumormacrolide antibiotic.J Antibiot 1985.38(11):p.1449-1452.
6.Teplova,V.V.,et al.,Bafilomycin A1is a potassium ionophore thatimpairs mitochondrial functions.Journal of Bioenergetics&Biomembranes,2007.39(4):p.321-329.
7.S Thudium,C.,et al.,Disruption of the V-ATPase functionality as away to uncouple bone formation and resorption-a novel target for treatment ofosteoporosis.Current Protein and Peptide Science,2012.13(2):p.141-151.
8.Hinton,A.,S.Bond,and M.Forgac,V-ATPase functions in normal anddisease processes.Pflügers Archiv-European Journal of Physiology,2009.457(3):p.589-598.
9.Farina,C.,et al.,Novel bone antiresorptive agents that selectivelyinhibit the osteoclast V-H+-ATPase.Cheminform,2001.56(1):p.113-116.
10.Pérez-Sayáns,M.,et al.,V-ATPase inhibitors and implication incancer treatment.Cancer treatment reviews,2009.35(8):p.707-713.
11.Mauvezin,C.,et al.,Autophagosome–lysosome fusion is independent ofV-ATPase-mediated acidification.Nat commun,2015.6:p.7007.
12.Del Poeta,M.,et al.,Synergistic antifungal activities ofbafilomycin A1,fluconazole,and the pneumocandin MK-0991/caspofungin acetate(L-743,873)with calcineurin inhibitors FK506and L-685,818 againstCryptococcus neoformans.Antimicrobial agents and chemotherapy,2000.44(3):p.739-746.
13.Li,L.-q.,et al.,Inhibition of autophagy by bafilomycin A1promoteschemosensitivity of gastric cancer cells.Tumor Biology,2016.37(1):p.653-659.
14.Zhang,W.,et al.,Characterization of the bafilomycin biosyntheticgene cluster from Streptomyces lohii.Chembiochem,2013.14(3):p.301-6.
15.Li,Z.,et al.,Complete elucidation of the late steps of bafilomycinbiosynthesis in Streptomyces lohii.Journal of Biological Chemistry,2017.292(17):p.7095-7104.
序列表
<110> 中国科学院青岛生物能源与过程研究所
<120> 一种巴弗洛霉素高产工程菌及其构建和应用
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1830
<212> DNA
<213> 海洋链霉菌(Streptomyces lohii bafG)
<400> 1
gtgcacgtgt cggcgccgag gcagcgcgtg gtcatggcag cgctcctcct caacgccaac 60
cgggtgatct cggtcgaccg catcaccgag tacgtctggg acggcgcccc gccgccgagt 120
gccgccgcga ccgtccgcac ctacgtgatg cgcctgcggc agtcgctggg cgagcacgcc 180
tccgcccgca tcctcacccg ggcgcccggc tacctcctcg aactcgggga gcacgagagc 240
gatctcggcc agttcgccgc ccaccgcagg cgcgcggcgg agctggccga gcgcggagac 300
ctggagggct cctccgccgc gctggccgag gcactcgccc tgtggcgcga ggagccgctg 360
gcggacatcc cgtcgcggac gctgcgcgat gtggagggac gttacctcca ggagctccgg 420
ctgcagacca tggagctgcg gttcgacgcg gagctggcgc tgctgcggca cgccgagatc 480
gtgccggagc tggtgcggct ggtgcgggag catcccttac gggaggccct ggtgggcaag 540
ttgatgctgg cgctcttccg ctcgggacgg cagtcggagg ccctggacct ctaccggcgc 600
acccgggtac tgctcgtcga acagctcggg gccgagcccg gcgcggatct gcgcgaggtc 660
caccggcaca tcctctcggc ccacgaccgg ccccgtacgc ccgacccgca ggagcggccc 720
gccccggccc cggagacagc cgccgcaccg gccgctgcca cggtccggga aagatcctgg 780
cccgatcctg cgcagcttcc ctcggtcccg ctgcccctgt cggcccgctc cgacgcactg 840
gcgcgggtgc ggcacttcct cacgaccggc acgatgcccg cgggcatggt ggcgacggcg 900
gtggtgaccg gccggggcgg tgtcggcaag agcgccctgg ccctgcacgc ggcgcacacc 960
atgcgcggct cctccgtaca cggccagctc tacgcggatc tcggcggggc ggagcggccg 1020
ctgaccgccc gggaggtgct gccgcggttc ctggcggacc tcggtgtgcc ccgggacgag 1080
atccccgggg aggagtcgga gcgggagagc ctctaccgct cgctcaccgc gggccgccgt 1140
ctgctggtgg tgctcgacaa cgcctccggc gccgcgcagg tgcggccgct gatcccgggc 1200
agcgggggca gcaggctgct ggtgaccagc cggcggcggc tggccgatct ggagggggcg 1260
cgcacccttc tgctcggccc gctggacgag gccgggtcgc tggagctgct gggcagcatc 1320
gtcggcacgg ccagggtcgg cggcgaacca cgggcggccc gtacggtggt gacggtctgc 1380
gcgggcctgc cgctggcgat ccggatcgcg gggacccggc tgctggaacg cccgcactgg 1440
agcatcgggc acctggcccg gcggctcacg gaggcccccc ggctgctgga cgaactgtgc 1500
gcgggcgata ccggtgtccg gccctgcctg gacgccgagg tggccgggct ccggcggtcg 1560
gcaccgggcg gaatcgaccc cgctgaggtg ctggccgcgc tgggcgccgc cggggcgtcc 1620
tcggtctccg gcggcgaggt cgcggtgatg gtcggctgcc cggaggcgca ggccgaggag 1680
gccctggact ccctggtcgt ggcgaatctg ctgggtgcgc ccgcgggggg ccgctaccgg 1740
ctggacgcgc tgcttcgggc gtacgcccgc gagcgtgcgc aggcggtcgc ggtacggcgg 1800
cacggccgct cctacatgcg cgccgggtga 1830
<210> 2
<211> 354
<212> DNA
<213> 海洋链霉菌(Streptomyces lohii orf1)
<400> 2
gtgacaccgt cagcgacctc tgaagagacc aagcccgcac cgcggccgcc gaggtccgag 60
cccgtcggcg acgcccgtcc ggcgggcggg gacccgtccg ccggcacggg tgtccggcgg 120
ctgaccgccg tggacgtccg catcctggaa ggtgtcgcgg tcggcacccc gaccgtccgg 180
ctggcggcat cgctctatct gagccgacag ggcgtcgagt accgcatcgg gctgatgatg 240
cgccatttcc aggccgcgaa ccgggccgca ctgatttccc gggcgcactc actcggtgtg 300
ctgagcgtcg gggcatggcc gccccgtgtc ctcccggaat tccttgaacc ctag 354
Claims (10)
1.一种巴弗洛霉素高产工程菌，其特征在于：在Streptomyces lohii野生株或突变株中过表达调控基因、其同源基因或与其功能等同体，所述调控基因为bafG和/或orf1；其中，调控基因BafG和Orf1的序列，分别为SEQ ID NO.1和SEQ ID NO.2。
2.按权利要求1所述巴弗洛霉素高产工程菌，其特征在于：所述突变株为S.lohiiΔorf2&orf3。
3.按权利要求1-2任意一项所述巴弗洛霉素高产工程菌，其特征在于：所述过表达调控基因、其同源基因或与其功能等同体的启动子来源于红霉素抗性基因启动子ermE*或其功能等同体。
4.按权利要求1-2任意一项所述巴弗洛霉素高产工程菌，其特征在于：所述过表达调控基因、其同源基因或与其功能等同体的载体为链霉菌整合型载体pSET152或其功能等同体。
5.一种权利要求1-2任意一项所述巴弗洛霉素高产工程菌的构建方法，其特征在于：
将调控基因为bafG和/或orf1基因与载体连接，分别克隆得到含有目的基因的表达载体，再分别将该表达载体转化进大肠杆菌，而后分别将转入表达载体的大肠杆菌与S.lohii野生株或突变株整合即获得巴弗洛霉素高产的S.lohii野生株工程菌或巴弗洛霉素高产的S.lohii突变株工程菌。
6.按权利要求5所述巴弗洛霉素高产工程菌的构建方法，其特征在于：所述载体为链霉菌整合型载体pSET152或其功能等同体。
7.一种权利要求1所述的巴弗洛霉素高产工程菌的应用，其特征在于：所述工程菌在生产制备巴弗洛霉素中的应用。
8.按权利要求7所述的巴弗洛霉素高产工程菌的应用，其特征在于：所述野生菌的工程菌在生产制备巴弗洛霉素中的应用。
9.按权利要求7所述的巴弗洛霉素高产工程菌的应用，其特征在于：所述突变菌株的工程菌在生产制备巴弗洛霉素A1中的应用。
10.按权利要求7所述的巴弗洛霉素高产工程菌的应用，其特征在于：将工程菌的孢子体于2×YT液体培养基中，30℃，220rpm培养2天，再按照1:10的体积比例转接种子液到发酵培养基中，30℃，250rpm培养7天，收集发酵液经HPLC定量/定性的检测巴弗洛霉素。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811634377.7A CN111378610B (zh) | 2018-12-29 | 2018-12-29 | 一种巴弗洛霉素高产工程菌及其构建和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811634377.7A CN111378610B (zh) | 2018-12-29 | 2018-12-29 | 一种巴弗洛霉素高产工程菌及其构建和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111378610A true CN111378610A (zh) | 2020-07-07 |
| CN111378610B CN111378610B (zh) | 2022-06-14 |
Family
ID=71220547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811634377.7A Expired - Fee Related CN111378610B (zh) | 2018-12-29 | 2018-12-29 | 一种巴弗洛霉素高产工程菌及其构建和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111378610B (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1688885A (zh) * | 2001-05-31 | 2005-10-26 | 莫纳什大学 | β细胞毒性大环内酯的化验 |
| CN103060248A (zh) * | 2011-10-19 | 2013-04-24 | 中国科学院上海有机化学研究所 | 一种构建基因工程fk506高产菌株的方法和筑波链霉菌高产菌株 |
| WO2015149006A2 (en) * | 2014-03-27 | 2015-10-01 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating ncoa4-mediated autophagic targeting of ferritin |
-
2018
- 2018-12-29 CN CN201811634377.7A patent/CN111378610B/zh not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1688885A (zh) * | 2001-05-31 | 2005-10-26 | 莫纳什大学 | β细胞毒性大环内酯的化验 |
| CN103060248A (zh) * | 2011-10-19 | 2013-04-24 | 中国科学院上海有机化学研究所 | 一种构建基因工程fk506高产菌株的方法和筑波链霉菌高产菌株 |
| WO2015149006A2 (en) * | 2014-03-27 | 2015-10-01 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating ncoa4-mediated autophagic targeting of ferritin |
Non-Patent Citations (2)
| Title |
|---|
| JIAN LI 等: "Macrolides of the bafilomycin family produced by Streptomyces sp. CS", 《J ANTIBIOT (TOKYO)》 * |
| ZHONG LI等: "Complete elucidation of the late steps of bafilomycin biosynthesis in Streptomyces lohii", 《JOURNAL OF BIOLOGICAL CHEMISTRY》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111378610B (zh) | 2022-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA001744B1 (ru) | Новые эритромицины и способы их получения | |
| Ren et al. | Enhancement of nystatin production by redirecting precursor fluxes after disruption of the tetramycin gene from Streptomyces ahygroscopicus | |
| CN110218244B (zh) | 化合物ilamycin F及其应用 | |
| NZ509306A (en) | Nocathiacin antibiotics | |
| EP2597152B1 (en) | Genetically engineered strain wsj-ia for producing isovaleryl spiramycin i. | |
| US8241872B2 (en) | Microorganism producing cyclic compound | |
| EP2615168A1 (en) | Process for producing reveromycin a or a synthetic intermediate thereof, process for producing compounds containing a spiroketal ring and novel antineoplastics, fungicides and therapeutic agents for bone disorders | |
| KR100476799B1 (ko) | 브로모티아쿠미신 화합물 | |
| CN111378610B (zh) | 一种巴弗洛霉素高产工程菌及其构建和应用 | |
| EP2261238B1 (en) | Cyclic compound and salt thereof | |
| US10590159B2 (en) | Lincomycin biosynthetic intermediates, method for preparation, and use thereof | |
| AU2013287626A1 (en) | UK-2 biosynthetic genes and method for improving UK-2 productivity using the same | |
| EP2327789B1 (en) | Signamycin, method for production thereof, and use thereof | |
| US20140228278A1 (en) | Antibiotics and methods for manufacturing the same | |
| CN110343650B (zh) | 一种产两性霉素b的重组结节链霉菌及其应用 | |
| KR20060110873A (ko) | 2-페닐벤조푸란 유도체, 이의 제조방법 및 이의 용도 | |
| KR101327798B1 (ko) | 아글루코반코마이신을 생산하는 미생물 | |
| CN108864221B (zh) | 阿克拉霉素类似物及其制法和用途 | |
| CN108456689A (zh) | 提高安丝菌素p-3生物合成产量的方法 | |
| WO2021236770A1 (en) | Novel antibiotic compositions and methods of making or using the same | |
| WO2015145152A1 (en) | Antimicrobial agents | |
| CN117778290A (zh) | 一株高产奥利万星直接前体的工程菌及其应用 | |
| CN117024447A (zh) | 聚醚化合物及其制备方法 | |
| JP2006527208A (ja) | 抗腫瘍活性を有するポリエンオキサゾール、及びストレプトミセス株を使用するその調製方法 | |
| CN115991687A (zh) | 一种二异戊烯基取代aspulvinone类化合物及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220614 |